- Home
- RMCF vs PASG Comparison
RMCF vs PASG Comparison
Compare RMCF & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RMCF | PASG |
|---|---|---|
| Founded | 1981 | 2017 |
| Country | United States | United States |
| Employees | N/A | 27 |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.2M | 26.0M |
| IPO Year | 2024 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RMCF | PASG |
|---|---|---|
| Price | $2.28 | $9.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $24.80 |
| AVG Volume (30 Days) | 17.6K | ★ 30.0K |
| Earning Date | 01-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $30,432,352.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.14 | $0.28 |
| 52 Week High | $2.99 | $20.00 |
Technical Indicators
Market Signals| Indicator | RMCF | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 43.04 | 58.49 |
| Support Level | $1.47 | $8.02 |
| Resistance Level | $2.22 | $10.15 |
| Average True Range (ATR) | 0.13 | 1.07 |
| MACD | -0.00 | 0.46 |
| Stochastic Oscillator | 28.70 | 72.26 |
Price Performance
Historical ComparisonAbout RMCF Rocky Mountain Chocolate Factory Inc.
Rocky Mountain Chocolate Factory Inc operates as a manufacturer of chocolate candies and confectionery products. The business activity of the firm functions through Franchising, Manufacturing, Retail Stores, U-Swirl Operations, and Other t. The products of the company include varieties of Clusters, Caramels, Creams, Toffees, Mints, and Truffles.
About PASG Passage Bio Inc.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.